Mizuho Securities analyst Steven Valiquette has maintained their neutral stance on HSIC stock, giving a Hold rating on February 25.
Steven Valiquette’s rating is based on several factors influencing Henry Schein’s current and future performance. The company’s recent financial results, including fourth-quarter revenues and earnings per share, aligned with prior negative announcements, indicating some challenges in meeting expectations. Additionally, while there was growth in U.S. and international dental sales, the increases were not as robust as initially anticipated, contributing to a cautious outlook.
Moreover, the 2025 earnings guidance provided by Henry Schein falls short of the prevailing market expectations, suggesting limited growth potential in the near term. Despite these concerns, the investment by KKR and their involvement in the board of directors is seen as a positive sign for the company’s long-term prospects. This strategic partnership is expected to enhance Henry Schein’s strategic outlook and succession planning, offering some optimism beyond the immediate challenges.
According to TipRanks, Valiquette is a 2-star analyst with an average return of 0.0% and a 53.22% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Cencora, Align Tech, and Henry Schein.
In another report released on February 25, Leerink Partners also maintained a Hold rating on the stock with a $80.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com